Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S grew net income 13.33% from 42.14bn to 47.76bn primarily through revenue growth (126.95bn to 140.80bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.91% growth in revenues contributed enough to still see net income improve.
Gross margin83.92%
Net profit margin32.14%
Operating margin42.24%
Return on assets26.81%
Return on equity72.19%
Return on investment51.95%
More ▼

Cash flow in DKKView more

In 2021, cash reserves at Novo Nordisk A/S fell by 1.51bn. However, the company earned 55.00bn from its operations for a Cash Flow Margin of 39.06%. In addition the company used 31.61bn on investing activities and also paid 25.49bn in financing cash flows.
Cash flow per share24.64
Price/Cash flow per share22.86
Book value per share33.15
Tangible book value per share13.30
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 25.46%, a higher figure than the previous year's 19.01%.
Current ratio0.9391
Quick ratio0.7412
Total debt/total equity0.3416
Total debt/total capital0.2546
More ▼

Growth rates in DKK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 14.29% and 15.15%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.16%
Div growth rate (5 year)6.47%
Payout ratio (TTM)38.11%
EPS growth(5 years)6.74
EPS (TTM) vs
TTM 1 year ago
15.26
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.